Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En fase 1 AAV-genterapforsøg, der evaluerer sikkerhed og foreløbig effektivitet af RP-A701 hos personer med bag3 udvidet kardiomyopati

30. september 2026 opdateret af: Rocket Pharmaceuticals Inc.

A Phase 1 Dose Escalation Trial Evaluating an Intravenously Administered Recombinant Adeno-associated Virus Serotype rh.74 (AAVrh.74) Vector Containing the Human BCL2-associated Athanogene 3 (BAG3) Gene Coding Sequence (RP-A701) in Subjects With Dilated Cardiomyopathy Arising From Pathogenic BAG3 Variants (Bag3-DCM)

This is a Phase 1, open-label, dose-escalation trial to characterize the safety, tolerability, and preliminary efficacy of RP-A701 following a single IV administration in high-risk adult patients with BAG3-DCM.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

8

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • California
      • San Diego, California, Forenede Stater, 92037
        • Rekruttering
        • University of California, San Diego
        • Ledende efterforsker:
          • Barry Greenberg, MD
        • Kontakt:
    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Rekruttering
        • Mayo Clinic
        • Ledende efterforsker:
          • John Giudicessi, MD, PhD
        • Kontakt:
    • South Carolina
      • Charleston, South Carolina, Forenede Stater, 29425
        • Rekruttering
        • Medical University of South Carolina
        • Ledende efterforsker:
          • Daniel Judge, MD
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Subjects are eligible for inclusion into the study only if all the following criteria apply:

  1. Male or female between 18 and 65 years of age at the time of signing the informed consent

  2. Capable of and willing to provide signed informed consent

  3. Clinical diagnosis of DCM defined as and requiring each of the following:

    1. Mild to moderate systolic dysfunction (LVEF ≥ 25% and ≤ 45%) by echocardiography or CMR performed within 3 months of enrollment.
    2. Absence of severe coronary artery disease (>70% stenosis) or active myocardial ischemia as the etiology of LV systolic dysfunction
    3. Absence of uncontrolled hypertension, significant cardiac valve disease (i.e., greater than moderate in severity), infiltrative disorder, or systemic disease known to cause cardiomyopathy.
  4. Documentation of a pathogenic or likely pathogenic variant in BAG3

  5. History of ICD implantation ≥ 3 months prior to enrollment

  6. NYHA Class II or III HF symptoms with stable HF therapeutic guideline-directed medical regimen for 30 days prior to enrollment

Exclusion Criteria:

  1. CV disease that may be related to a genetic etiology other than a BAG3 pathogenic or likely pathogenic variant.
  2. Previous participation in a study of gene transfer or gene editing.
  3. I.V. inotropic, vasodilator, or diuretic therapy ≤ 30 days prior to enrollment.
  4. History of intracardiac thrombosis or arterial thromboembolic events
  5. Severe RV dysfunction assessed by echocardiogram or CMR ≤ 12 months prior to screening
  6. LVEF < 25% by echocardiogram or CMR at ≤ 3 months prior to screening
  7. NYHA Class I or IV HF

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Single ascending dose of RP-A701 in up to 2 consecutive cohorts

Participants will receive a single intravenous dose of RP-A701 on Day 0 and will be followed for up to two years

One-time treatment with a single ascending dose

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of Treatment-emergent Adverse Events (TEAE)
Tidsramme: Baseline up to End of Study (up to 24 months post-infusion)

Number of participants with Adverse Events following a single IV dose of RP-A701

Baseline up to End of Study (up to 24 months post-infusion)
Incidence of Treatment-emergent Serious Adverse Events (SAE).
Tidsramme: Baseline up to End of Study (up to 24 months post-infusion)

Number of participants with Serious Adverse Events (SAE) following a single IV dose of RP-A701

Baseline up to End of Study (up to 24 months post-infusion)
Incidence of Dose Limiting Toxicities (DLT).
Tidsramme: Baseline up to End of Study (up to 24 months post-infusion)

Number of participants with Dose Limiting Toxicities (DLT) following a single IV dose of RP-A701

Baseline up to End of Study (up to 24 months post-infusion)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To assess the impact of RP-A701 on features of cardiovascular function.
Tidsramme: Baseline up to End of Study (up to 24 months post-infusion)

Change in measures of LV systolic function, including LV ejection fraction (LVEF), LV global longitudinal strain.

Baseline up to End of Study (up to 24 months post-infusion)
To assess the impact of RP-A701 on features of cardiovascular function.
Tidsramme: Baseline up to End of Study (up to 24 months post-infusion)

Change in peak oxygen consumption (VO2) or ventilatory efficiency (VE/VCO2 slope) by cardiopulmonary exercise test (CPET)

Baseline up to End of Study (up to 24 months post-infusion)
To assess the impact of RP-A701 on features of cardiovascular function.
Tidsramme: Baseline up to End of Study (up to 24 months post-infusion)

Change in 6-minute walk distance.

Baseline up to End of Study (up to 24 months post-infusion)
To assess the extent of RP-A701 transduction and protein expression.
Tidsramme: Baseline up to End of Study (up to 24 months post-infusion)

Change in BAG3 myocardial protein expression

Baseline up to End of Study (up to 24 months post-infusion)
To assess the impact of RP-A701 on features of heart failure (HF).
Tidsramme: Baseline up to End of Study (up to 24 months post-infusion)

Change in symptoms of HF assessed by New York Heart Association (NYHA) class.

Baseline up to End of Study (up to 24 months post-infusion)
To assess the impact of RP-A701 on quality of life.
Tidsramme: Baseline up to End of Study (up to 24 months post-infusion)

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ-12) Overall Summary Score.

Baseline up to End of Study (up to 24 months post-infusion)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. april 2026

Primær færdiggørelse (Anslået)

1. juni 2029

Studieafslutning (Anslået)

1. juni 2029

Datoer for studieregistrering

Først indsendt

25. juli 2025

Først indsendt, der opfyldte QC-kriterier

20. august 2025

Først opslået (Faktiske)

22. august 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

30. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner